NVAX
Price
$4.28
Change
-$0.02 (-0.47%)
Updated
Apr 12, 6:59 PM EST
22 days until earnings call
RCUS
Price
$16.60
Change
-$0.68 (-3.94%)
Updated
Apr 12, 6:59 PM EST
22 days until earnings call
Ad is loading...

Compare trend and price NVAX vs RCUS

Header iconNVAX vs RCUS Comparison
Open Charts NVAX vs RCUSBanner chart's image
Novavax
Price$4.28
Change-$0.02 (-0.47%)
Volume$2.43M
CapitalizationN/A
Arcus Biosciences
Price$16.60
Change-$0.68 (-3.94%)
Volume$111.05K
CapitalizationN/A
View a ticker or compare two or three
NVAX vs RCUS Comparison Chart

Loading...

NVAXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
RCUSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
NVAX vs. RCUS commentary
Apr 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVAX is a Hold and RCUS is a Buy.

COMPARISON
Comparison
Apr 15, 2024
Stock price -- (NVAX: $4.65 vs. RCUS: $18.48)
Brand notoriety: NVAX: Notable vs. RCUS: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NVAX: 52% vs. RCUS: 55%
Market capitalization -- NVAX: $650.78M vs. RCUS: $1.68B
NVAX [@Biotechnology] is valued at $650.78M. RCUS’s [@Biotechnology] market capitalization is $1.68B. The market cap for tickers in the [@Biotechnology] industry ranges from $568.84B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVAX’s FA Score shows that 0 FA rating(s) are green whileRCUS’s FA Score has 0 green FA rating(s).

  • NVAX’s FA Score: 0 green, 5 red.
  • RCUS’s FA Score: 0 green, 5 red.
According to our system of comparison, RCUS is a better buy in the long-term than NVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVAX’s TA Score shows that 5 TA indicator(s) are bullish while RCUS’s TA Score has 6 bullish TA indicator(s).

  • NVAX’s TA Score: 5 bullish, 4 bearish.
  • RCUS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, RCUS is a better buy in the short-term than NVAX.

Price Growth

NVAX (@Biotechnology) experienced а -3.33% price change this week, while RCUS (@Biotechnology) price change was +12.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.71%. For the same industry, the average monthly price growth was +6.49%, and the average quarterly price growth was +103.81%.

Reported Earning Dates

NVAX is expected to report earnings on May 07, 2024.

RCUS is expected to report earnings on May 07, 2024.

Industries' Descriptions

@Biotechnology (+4.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for NVAX with price predictions.
OPEN
A.I.dvisor published
a Summary for RCUS with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
RCUS($1.68B) has a higher market cap than NVAX($651M). NVAX (-3.125) and RCUS (-3.246) have similar YTD gains . RCUS has higher annual earnings (EBITDA): -291M vs. NVAX (-487.39M). RCUS has more cash in the bank: 759M vs. NVAX (569M). RCUS has less debt than NVAX: RCUS (11M) vs NVAX (229M). NVAX has higher revenues than RCUS: NVAX (556M) vs RCUS (117M).
NVAXRCUSNVAX / RCUS
Capitalization651M1.68B39%
EBITDA-487.39M-291M167%
Gain YTD-3.125-3.24696%
P/E RatioN/A14.39-
Revenue556M117M475%
Total Cash569M759M75%
Total Debt229M11M2,082%
FUNDAMENTALS RATINGS
NVAX vs RCUS: Fundamental Ratings
NVAX
RCUS
OUTLOOK RATING
1..100
7513
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
58
Fair valued
PROFIT vs RISK RATING
1..100
10075
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
7956
P/E GROWTH RATING
1..100
10096
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCUS's Valuation (58) in the Pharmaceuticals Major industry is in the same range as NVAX (86) in the Biotechnology industry. This means that RCUS’s stock grew similarly to NVAX’s over the last 12 months.

RCUS's Profit vs Risk Rating (75) in the Pharmaceuticals Major industry is in the same range as NVAX (100) in the Biotechnology industry. This means that RCUS’s stock grew similarly to NVAX’s over the last 12 months.

RCUS's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as NVAX (100) in the Biotechnology industry. This means that RCUS’s stock grew similarly to NVAX’s over the last 12 months.

RCUS's Price Growth Rating (56) in the Pharmaceuticals Major industry is in the same range as NVAX (79) in the Biotechnology industry. This means that RCUS’s stock grew similarly to NVAX’s over the last 12 months.

RCUS's P/E Growth Rating (96) in the Pharmaceuticals Major industry is in the same range as NVAX (100) in the Biotechnology industry. This means that RCUS’s stock grew similarly to NVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVAXRCUS
RSI
ODDS (%)
Bearish Trend 15 days ago
89%
Bearish Trend 15 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 15 days ago
87%
Bearish Trend 15 days ago
84%
Momentum
ODDS (%)
Bearish Trend 15 days ago
86%
Bearish Trend 15 days ago
82%
MACD
ODDS (%)
Bearish Trend 15 days ago
85%
Bullish Trend 15 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 15 days ago
90%
Bullish Trend 15 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 15 days ago
88%
Bearish Trend 15 days ago
76%
Advances
ODDS (%)
Bullish Trend about 1 month ago
82%
Bullish Trend 19 days ago
81%
Declines
ODDS (%)
Bearish Trend 15 days ago
90%
Bearish Trend 25 days ago
83%
BollingerBands
ODDS (%)
N/A
Bullish Trend 15 days ago
77%
Aroon
ODDS (%)
Bullish Trend 15 days ago
83%
Bullish Trend 15 days ago
90%
View a ticker or compare two or three
Ad is loading...
NVAXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
RCUSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BRKUX13.000.02
+0.15%
MFS Blended Research Em Mkts Eq R4
GEMCX18.27N/A
N/A
Goldman Sachs Emerging Markets Eq C
HAMVX26.73-0.14
-0.52%
Harbor Mid Cap Value Instl
AAERX19.10-0.10
-0.52%
American Beacon International Eq R6
VMVAX80.19-0.60
-0.74%
Vanguard Mid-Cap Value Index Admiral

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with CRSP. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
-2.72%
CRSP - NVAX
47%
Loosely correlated
+0.03%
THRD - NVAX
42%
Loosely correlated
-7.42%
XNCR - NVAX
38%
Loosely correlated
-0.77%
SYRE - NVAX
38%
Loosely correlated
-2.29%
MRNA - NVAX
35%
Loosely correlated
-0.90%
More

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with ITOS. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then ITOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
-2.12%
ITOS - RCUS
60%
Loosely correlated
-2.13%
NTLA - RCUS
47%
Loosely correlated
-1.05%
AGIO - RCUS
46%
Loosely correlated
-1.23%
OCUL - RCUS
44%
Loosely correlated
-4.51%
VSTM - RCUS
44%
Loosely correlated
-0.42%
More